Pharma giants Sanofi and Merck & Co. each have big ambitions in vaccines, and ahead of the new year, the companies secured FDA approval for a six-in-one shot to be marketed as Vaxelis.
When supplies are strained, what gives? For Merck & Co., in the midst of global production constraints, it's phasing out shipments of cut-rate RotaTeq doses to Africa